DBV Technologies S.A. (DBVT) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Solid Biosciences (SLDB) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 8.1% versus a loss of 31.4%. Over five years, DBVT leads with a -7.8% price change compared with -79.8% for SLDB. Solid Biosciences is the larger company by market cap ($731.3 million vs $600.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | SLDB |
|---|---|---|
| Share price | $9.55 | $6.82 |
| Market cap | $600.20M | $731.28M |
| 1-day change | -2.25% | -0.44% |
| YTD return | -49.03% | +20.92% |
| 1-year return | -31.39% | +8.08% |
| 5-year return | -7.83% | -79.79% |
| EPS (TTM) | $-3.50 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.19 | $11.45 |
| 52-week low | $9.36 | $3.79 |
| Distance from 52-week high | -63.53% | -40.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +304.50% | +173.02% |
| Average volume | 339.25K | 1.10M |
| Shares outstanding | 62.85M | 107.23M |
| Employees | 170 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed DBVT by 39.5 percentage points over the past year.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 170 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
DBVT vs SLDB FAQ
Which is bigger, DBV Technologies S.A. or Solid Biosciences?
Solid Biosciences (SLDB) is larger, with a market capitalization of $731.28M compared with $600.20M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or SLDB?
SLDB returned +8.08% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.